Positive findings for postsurgical acute pain relief from the pivotal phase 3 ALLEVIATE-2 trial complete the development program, allowing plans for NDA submission.

Elizabeth Swanson, MD, discusses the changing face of HFMD, focusing on the increasingly prevalent coxsackievirus A6 strain and its unique characteristics

Higher levels of cardiovascular health were associated with lower levels of neurofilament light chain across age, sex, race/ethnicity, and Alzheimer disease risk.

In an interview at AAD 2025, Dr Yu emphasized the importance of managing contact dermatitis early and effectively to prevent long-term complications.

Elinzanetant, a first in class dual neurokinin-1 and 3 (NK-1,3) receptor antagonist in late-stage clinical development, has a US PDUFA date set for July 26, 2025.

Your daily dose of the clinical news you may have missed.

Analysis of data from the donanemab TRAILBLAZER development program underscores the essential role of patient selection and treatment monitoring.

Cervical cancer screening rates remained below prepandemic levels, while rates for breast and colorectal cancers rebounded from pandemic declines.

Brian S Kim, MD, a leading investigator in the study of itch physiology, discusses the marked progress made in understanding the sensation and targeting its treatment.

The impact of childhood onset AD on adult psychosocial experience, including employment and the decision to become a parent, is profound, this study reveals.

Your daily dose of the clinical news you may have missed.

The menopausal symptom and lifestyle management app provides guideline-based CBT principles to augment hormone therapy or even to replace it for some women.

Highlights include new data on roflumilast cream 0.15%, an investigational anti-OX40 ligand monoclonal antibody, and more.

CagriSema proved superior to placebo in the pivotal phase 3 trial but as in the earlier REDEFINE 1 study fell short of the 25% or greater reduction Novo Nordisk projected.

AAD 2025. JiaDe Yu, MD, discusses key clinical signs of pediatric ACD, when to consider patch testing, and how identifying contact allergens can improve patient care.

Elizabeth Swanson, MD, breaks down the role of the Herpes Simplex Virus in 3 special circumstances, part of her AAD 2025 presentation, "Big Rashes In Little Patients."

AAD 2025. Guttman, among the world's foremost researchers in dermatology, toplined how far the field has come in her "Hot Topics" presentation on the final day of the 2025 AAD.

Omlyclo is indicated for the treatment of moderate to severe persistent asthma, chronic rhinosinusitis with nasal polyps, IgE-mediated food allergy, and chronic spontaneous urticaria.

Data on delgocitinib from the DELTA development program highlight efficacy of the topical JAK inhibitor for treatment of chronic hand eczema.

JiaDe Yu, MD, shares key takeaways from his presentation on pediatric allergic contact dermatitis.